Daniel Horowitz, Whistleblowers Share DOD Medical Data Thar Blows Vaccine Safety Debate Wide Open.
Data, transparency, and surveillance. That is what has been missing from the greatest experiment on humans of all time throughout this pandemic. Now, military medical whistleblowers have come forward with what they claim is perhaps the most accurate and revealing data set on vaccine safety one could possibly find.
On Monday, during Sen. Ron Johnson’s five-hour hearing on a “COVID-19: Second Opinion,” Ohio attorney Thomas Renz, who has been representing clients suing the vaccine mandates, presented DOD medical billing data from the Defense Medical Epidemiology Database (DMED) that paints a shockingly disturbing picture of the health of our service members in 2021:
• Neurological issues: a 1,000% increase, from a baseline average of 82,000 to 863,000
• Cancer: an almost 300% increase in cancer diagnoses (from a five-year average of 38,700 per year to 114,645 in the first 11 months of 2021)
• Pulmonary embolisms: a 467% increase
• Myocardial infarction: a 269% increase
• Bell’s palsy: a 291% increase
• Miscarriages: a 300% increase in 2021 over the five-year average. The five-year average was 1,499 codes for miscarriages per year. During the first 10 months of 2021, it was 4,182.
• Congenital malformations (for children of military personnel): a 156% increase
• Female infertility: a 471% increase
DMED is quite literally an epidemiological surveillance program designed for the express purpose of detecting surges in illness and injury to make sure the military is combat-ready.
It’s about national security even more than public health.
Why would the military not have blown the whistle and warned the CDC right away about this data?
On the military health system website, the Armed Forces Health Surveillance Division (AFHSD) is described as “the central epidemiologic resource for the U.S. Armed Forces, conducting medical surveillance to protect those who serve our nation in uniform and allies who are critical to our national security interests.”
Experts question lack of clinical data to support FDA decision on monoclonal antibody treatments
The U.S. Food and Drug Administration used the results of laboratory experiments in its sudden and unexpected decision to revoke the emergency use authorizations for certain monoclonal antibody treatments for COVID-19, stating that data showed the treatments were ineffective against the Omicron variant.
On Monday, the FDA announced that the Eli Lilly and the REGEN-COV treatments would no longer be made available to health care providers in areas where Omicron is the dominant COVID-19 variant, including states like Florida, where the treatments have been accessible for months. The decision was slammed by Florida Gov. Ron DeSantis (R), who has encouraged the use of monoclonal antibodies as an effective early treatment for those infected with coronavirus. In a statement responding to the announcement, DeSantis criticized the Biden administration for taking away the treatment option “without a shred of clinical data to support this action.”